Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last261 to 280 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Cases vs Controls: Prevalence of Melanoma Skin Cancer in Adult People Diagnosed With Vitiligo | 85 of 6,360 27 of 25,439 | 1.2 points 1.0 to 1.5 | 31,799 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Cases vs Controls: Prevalence of Actinic Keratoses in Adult People Diagnosed With Vitiligo | 111 of 6,360 363 of 25,439 | 0.3 points -0.0 to 0.7 | 31,799 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Cases vs Controls: Prevalence of Skin Cancer in Adult People Diagnosed With Vitiligo | 66 of 6,360 293 of 25,439 | -0.1 points -0.4 to 0.2 | 31,799 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Cases vs Controls: Prevalence of Squamous Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo | 13 of 6,360 72 of 25,439 | -0.1 points -0.2 to 0.1 | 31,799 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Cases vs Controls: Prevalence of Basal Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo | 31 of 6,360 161 of 25,439 | -0.1 points -0.3 to 0.1 | 31,799 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Atorvastatin vs Simvastatin: Number of Participants With Post-index Cardiovascular (CV) Events | 700 of 11,470 1,012 of 20,132 | 1.1 points 0.6 to 1.6 | 31,602 | NCT01304641 Cardiovascular Events Based On Statin Initiation In The Elderly |
| Cases vs Controls (reference group): Risk of Anxiety Disorder Within Adult Patients With Vitiligo | 122 of 6,655 382 of 24,834 | 0.3 points -0.0 to 0.7 | 31,489 | NCT04953338 Mental Health Associations With Vitiligo |
| Targeted Oral Azithromycin vs Targeted Oral Placebo: All-cause Mortality Rate in Individually Randomized Children at 4-12 Weeks of Age | 82 of 15,734 75 of 15,701 | 0.0 points -0.1 to 0.2 | 31,435 | NCT03676764 Community Health Azithromycin Trial in Burkina Faso |
| Acute Ischemic Stroke (AIS) Patients Aged >80 Years Who Received IV Rt-PA (Alteplase) vs Acute Ischemic Stroke (AIS) Patients Aged 18 to 80 Years Who Received IV Rt-PA (Alteplase): Number of Patients With Stroke Recurrence During Hospitalization | 369 of 3,332 2,039 of 28,086 | 3.8 points 2.7 to 5.0 | 31,418 | NCT05395351 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization |
| Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Serostatus With Onset At Least 1 Day After the First Day 1 Vaccination | 115 of 15,708 259 of 15,592 | -0.9 points -1.2 to -0.7 | 31,300 | NCT04614948 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults |
| Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With Serious Adverse Events (SAEs) | 104 of 15,705 136 of 15,588 | -0.2 points -0.4 to -0.0 | 31,293 | NCT04614948 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults |
| Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With Medically-Attended Adverse Events (MAAEs) | 1,033 of 15,705 1,003 of 15,588 | 0.1 points -0.4 to 0.7 | 31,293 | NCT04614948 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults |
| Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With Adverse Events of Special Interest (AESIs) | 2 of 15,705 1 of 15,588 | 0.0 points -0.0 to 0.0 | 31,293 | NCT04614948 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults |
| Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double-Blind: Number of Participants With MAAEs Leading to Study Discontinuation | 4 of 15,705 8 of 15,588 | -0.0 points -0.1 to 0.0 | 31,293 | NCT04614948 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults |
| People With Alopecia Areata vs People Without Alopecia Areata (Reference Gropup): Likelihood of Recurrent Major Depressive Disorder | 835 of 6,183 2,264 of 24,718 | 4.3 points 3.4 to 5.3 | 30,901 | NCT05727306 Healthcare Disparities in Alopecia Areata |
| People With Alopecia Areata vs People Without Alopecia Areata (Reference Group): Likelihood of Depressive Episodes | 1,217 of 6,183 3,576 of 24,718 | 5.2 points 4.1 to 6.3 | 30,901 | NCT05727306 Healthcare Disparities in Alopecia Areata |
| People With Alopecia Areata vs People Without Alopecia Areata (Reference Group): Likelihood of Anxiety Disorder | 1,113 of 6,183 3,188 of 24,718 | 5.1 points 4.1 to 6.2 | 30,901 | NCT05727306 Healthcare Disparities in Alopecia Areata |
| AZD1222 vs Placebo: Number of Participants With COVID-19 Severe or Critical Symptomatic Illness Post First Dose of Study Intervention | 5 of 20,589 16 of 10,300 | -0.1 points -0.2 to -0.1 | 30,889 | NCT04516746 Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults |
| AZD1222 vs Placebo: Number of Participants With COVID-19 Symptomatic Illness Post First Dose of Study Intervention | 287 of 20,589 303 of 10,300 | -1.5 points -1.9 to -1.2 | 30,889 | NCT04516746 Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults |
| Anacetrapib vs Placebo Anacetrapib: Number of Participants With Major Coronary Event | 1,640 of 15,225 1,803 of 15,224 | -1.1 points -1.8 to -0.4 | 30,449 | NCT01252953 REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=14
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04969419-058d8e05",
"title": "Cases vs Controls: Prevalence of Melanoma Skin Cancer in Adult People Diagnosed With Vitiligo",
"summary": "85 of 6360 against 27 of 25439; risk difference 1.2 points, 95% interval 1.0 to 1.5; NCT04969419, Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo",
"record": "/library/comparisons/NCT04969419-058d8e05",
"nct_id": "NCT04969419",
"kind": "outcome",
"participants": 31799,
"risk_difference": {
"value": 0.012303417399273785,
"lower": 0.009715262855959066,
"upper": 0.015451245198251876
},
"group_1": "85 of 6,360",
"group_2": "27 of 25,439",
"difference": "1.2 points",
"interval": "1.0 to 1.5",
"trial_title": "Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo"
},
{
"id": "NCT04969419-20b7519f",
"title": "Cases vs Controls: Prevalence of Actinic Keratoses in Adult People Diagnosed With Vitiligo",
"summary": "111 of 6360 against 363 of 25439; risk difference 0.3 points, 95% interval -0.0 to 0.7; NCT04969419, Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo",
"record": "/library/comparisons/NCT04969419-20b7519f",
"nct_id": "NCT04969419",
"kind": "outcome",
"participants": 31799,
"risk_difference": {
"value": 0.003183401358929647,
"lower": -0.00013134124876132457,
"upper": 0.006968036039955014
},
"group_1": "111 of 6,360",
"group_2": "363 of 25,439",
"difference": "0.3 points",
"interval": "-0.0 to 0.7",
"trial_title": "Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=15",
"request_id": "x9i0-_2JE79Bj92R"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant